Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
4(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
30%
Ph phase_1
7
70%

Phase Distribution

7

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
7(70.0%)
Phase 2Efficacy & side effects
3(30.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(5)

Detailed Status

Completed5
Active, not recruiting2
Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
4
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (70.0%)
Phase 23 (30.0%)

Trials by Status

active_not_recruiting220%
recruiting220%
not_yet_recruiting110%
completed550%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT07220460Phase 2

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

Recruiting
NCT06849791Phase 1

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Active Not Recruiting
NCT06846320Phase 2

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Recruiting
NCT06605599Phase 2

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

Completed
NCT07024797Phase 1

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants

Completed
NCT07071532Phase 1

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Healthy Adult Participants

Active Not Recruiting
NCT06953934Phase 1

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

Not Yet Recruiting
NCT06300580Phase 1

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers

Completed
NCT06024239Phase 1

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Completed
NCT05738850Phase 1

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10